Medpace (MEDP) – Investment Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Medpace (NASDAQ: MEDP):

• 7/24/2026 – Medpace had its price target raised by Royal Bank Of Canada from $484.00 to $692.00. They now have an “outperform” rating on the stock.
• 7/24/2026 – Medpace had its price target raised by Mizuho from $586.00 to $665.00. They now have an “outperform” rating on the stock.
• 7/24/2026 – Medpace had its price target raised by BMO Capital Markets from $400.00 to $600.00. They now have a “market perform” rating on the stock.
• 7/24/2026 – Medpace had its price target raised by TD Cowen from $419.00 to $492.00. They now have a “hold” rating on the stock.
• 7/24/2026 – Medpace had its price target raised by Truist Financial Corporation from $462.00 to $609.00. They now have a “hold” rating on the stock.
• 7/24/2026 – Medpace had its price target raised by Robert W. Baird from $547.00 to $624.00. They now have a “neutral” rating on the stock.
• 7/23/2026 – Medpace was given a new $600.00 price target by Barclays PLC.
• 7/23/2026 – Medpace was given a new $620.00 price target by Leerink Partners.
• 7/23/2026 – Medpace had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $535.00 price target on the stock.
• 7/13/2026 – Medpace had its price target raised by Mizuho from $495.00 to $586.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – Medpace had its “neutral” rating reaffirmed by Robert W. Baird. They now have a $547.00 price target on the stock, up from $477.00.
• 7/7/2026 – Medpace was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $515.00 price target on the stock, up from $490.00.
• 7/2/2026 – Medpace had its “hold (c+)” rating reaffirmed by Weiss Ratings.

Insider Activity

In other Medpace news, CEO August J. Troendle sold 3,510 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.01, for a total transaction of $2,106,035.10. Following the sale, the chief executive officer directly owned 638,946 shares of the company’s stock, valued at $383,373,989.46. The trade was a 0.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 31,087 shares of company stock worth $16,203,054. 20.50% of the stock is currently owned by corporate insiders.

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.